| Patient | Emily Dickinson |
|---|---|
| Date of birth | 1971-12-10 |
| Identifiers | MRN HR-NI023-SYN; SSN (made up) 000-23-6081 |
| Document date | 2026-06-01 |
| Author | Lucinda Hartwell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month kidney and blood pressure review at home. [S]
Ms. Dickinson is seen at home six weeks after her gastroenteritis. The repeat metabolic panel planned for two to three days after the sick visit was not drawn: she felt better by the second day and asked the phlebotomy service not to come. After a nurse call she restarted losartan, dapagliflozin, and amlodipine on the third day, once she had eaten and drunk normally for 24 hours. She has felt well since. Her home blood pressure averages 122/76. She has had no headaches for six weeks, sleeps about seven hours, and is writing full mornings. She has had no ankle swelling on amlodipine and no lightheadedness. She keeps the sick-day card in her medicine cabinet. [S]
| Element | Detail |
|---|---|
| Interval illness | Viral gastroenteritis six weeks ago with a prerenal creatinine rise; recovered |
| Missed check | Metabolic panel planned for two to three days after the sick visit was not drawn |
| Medicines | Restarted on the third day after a nurse call; taken daily since |
| Home blood pressure | Average 122/76 mmHg |
| Symptoms | No headaches for six weeks; sleeping about seven hours; no ankle swelling |
| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No nausea, vomiting, or diarrhea since recovery |
| Cardiovascular | Negative | No ankle swelling, palpitations, or lightheadedness |
| Neurological | Negative | No headaches for six weeks |
| Psychiatric | Negative | Mood good; PHQ-9 3 |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter) | Two tablets as needed, up to twice a day | Oral route | 2025-10-01 to 2026-01-12 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 to 2026-02-02 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-02 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 2026-01-12 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-02 | active | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-03-02 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-01 | Body height | 163 | cm | S |
| 2026-06-01 | Body weight | 53.2 | kg | S |
| 2026-06-01 | Body mass index (BMI) [Ratio] | 20 | kg/m2 | S |
| 2026-06-01 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-06-01 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-06-01 | Heart rate | 70 | /min | S |
| 2026-06-01 | Respiratory rate | 14 | /min | S |
| 2026-06-01 | Body temperature | 36.6 | Cel | S |
| 2026-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-01 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-01 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 2026-06-01 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 6-21 mg/dL | High | S |
| 2026-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 1.3 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 2026-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 49 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 2026-06-01 | Glucose [Mass/volume] in Serum or Plasma | 91 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-01 | Albumin/Creatinine [Mass Ratio] in Urine | 118 | mg/g | <=30 mg/g | High | S |
| 2026-06-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 2026-06-01; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, at her writing table |
| Cardiovascular | Regular rhythm; no murmur; no ankle edema |
| Mouth | Moist mucous membranes |
| Mental status | Alert and engaged; mood "well"; reactive affect |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate | active | confirmed | N18.31 | S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists. |
| Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension | active | confirmed | I12.9 | S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists. |
| Vitamin D deficiency with a mildly raised PTH in chronic kidney disease | active | confirmed | E55.9 | S — Synthetic laboratory finding at the intake visit. |
| Viral gastroenteritis with volume depletion and a prerenal rise in creatinine while taking losartan and dapagliflozin; resolved | resolved | confirmed | A08.4 | S — Synthetic illness at an unscheduled home visit, chosen to teach sick-day rules in chronic kidney disease; it does not echo any documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Metabolic panel two to three days after the prerenal creatinine rise | Within days after acute kidney injury or a sick-day pause | Deferred | Not drawn, a deviation from the plan: she felt better on the second day and declined the home draw, and the medicines were restarted after a nurse call without a recheck. No harm, judging by today's creatinine of 1.30 mg/dL and potassium of 4.7 mmol/L. Corrective action: after any kidney injury, the recheck is booked as a firm home draw before the clinician leaves, and the nurse confirms it was done before advising a restart |
| Laboratory | Metabolic panel with each eGFR draw | With each eGFR draw; more often on an ARB or SGLT2 inhibitor | Completed today | Potassium 4.7 mmol/L, bicarbonate 24 mmol/L, creatinine 1.30 mg/dL, eGFR 49 |
| Laboratory | Urine albumin-creatinine ratio | Twice a year at G3a A2 (KDIGO heat map); about 3 months after starting treatment to judge response | Completed today | 118 mg/g, down about half from 240 |
| Examination | Standardized office and home blood pressure | Every visit | Completed today | 124/76 mmHg at the home visit; home average 122/76 |
| Examination | Weight and cardiac auscultation | Every visit | Completed today | 53.2 kg; regular rhythm; no edema on amlodipine |
| Survey | PHQ-9 | Yearly with hypertension; repeat if symptoms change | Completed today | 3, down from 6 as headaches and sleep improved |
| Medication safety | Medication review: NSAID avoidance, sick-day rules, and SGLT2 inhibitor safety | Every visit | Completed today | No NSAIDs; no genital or urinary symptoms; sick-day card in place |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Completed today | HepB-CpG dose 1 given today; PCV20 in January; influenza due in the autumn |
| Laboratory | Calcium, phosphate, PTH, and 25-hydroxyvitamin D | Every 6 to 12 months at G3a; vitamin D repeated after repletion | Due | At the six-month review, about eight months after baseline |
| Self-management | Sodium, activity, and home readings | Every visit | Completed today | Low-salt cooking; garden work most afternoons; weekly home readings |
Goal progress:
Immunizations given today: Hepatitis B vaccine, CpG-adjuvanted (HepB-CpG), dose 1 of 2 [S]
Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026)
Follow-up: Video visit in about four months with home vital signs and home blood and urine tests. Next scheduled visit 2026-09-28: video visit for the six-month kidney review, with home vital signs and home blood tests. [S]